Scorpion Capital said via Twitter: “We just took the next step in our $HRMY Harmony Biosciences patent challenge by filing a Petition for Supervisory Review with the director of the Patent Trial and Appeals Board to reverse the Aug 24 Office Action and institute patent re-examination. Note that the Aug 24 action acknowledged that our petition posed a Substantial Question of Patentability, concluding only (erroneously, in our view) that the question had already been considered by the original patent examiner during prosecution.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HRMY:
- Harmony announces U.S. FDA granted Orphan Drug designation to pitolisant
- Harmony Biosciences initiated with a Buy at Berenberg
- Harmony Biosciences receives FDA orphan drug designation for pitolisant
- Harmony Biosciences patent news ‘clear positive,’ says Mizuho
- Harmony Biosciences comments on ‘favorable’ decision by USPTO on WAKIX